Cover Image
市場調查報告書

肺動脈高血壓 (PAH):市場考察,流行病學及市場預測

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2027

出版商 DelveInsight Business Research LLP 商品編碼 535890
出版日期 內容資訊 英文 116 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肺動脈高血壓 (PAH):市場考察,流行病學及市場預測 Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2027
出版日期: 2018年06月01日 內容資訊: 英文 116 Pages
簡介

本報告提供肺動脈高血壓 (PAH)的疾病概要及主要7個市場 (美國,EU5個國家,日本) 的流行病學與市場情況的相關分析,治療藥市場收益,實施的治療方法,及流行病學的預測 (患病人數等) 。

目錄

第1章 簡介

第2章 肺動脈高血壓 (PAH)市場概要

第3章 肺動脈高血壓 (PAH) :概要

  • 徵兆、症狀
  • 肺動脈高血壓 (PAH)的分類
  • PAH的功能分類
  • 流行病學
  • 風險要素
  • 病理學
  • 診斷
  • 治療

第4章 流行病學、患者人口

第5章 要點

第6章 人口、預測參數

第7章 市場PAH的患病人數:主要7個國家

第8章 美國

  • PAH患病人數
  • PAH患病人數:各子類型
  • PAH患病人數:性別

第9章 德國

第10章 法國

第11章 義大利

第12章 西班牙

第13章 英國

第14章 日本

第15章 治療流程

  • 美國
  • CHEST的指南
  • 歐洲
  • European Society of Cardiology (ESC) 及 the European Respiratory Society (ERS)的指南

第16章 未滿足需求

第17章 上市藥

  • 認證、市場影響

第18章 上市藥:各企業

  • United Therapeutics Corporation
  • Actelion Pharmaceuticals Ltd.
  • GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
  • Bayer AG
  • Pfizer

第19章 上市藥的安全性、功效

第20章 新的治療方法

第21章 全球市場的展望:肺動脈高血壓 (PAH)

第22章 全球市場規模:肺動脈高血壓 (PAH)

  • 前提條件
  • 市場規模
  • 主要7個國家的PAH的市場規模

第23章 美國市場分析、預測

  • 市場展望
  • 前提條件
  • 市場規模

第24章 市場分析、預測EU5個國家

第25章 其他歐洲 (RoE) 市場分析、預測

第26章 日本市場分析、預測

第27章 其他 (ROW) 市場分析、預測

第28章 市場成長的促進要素

第29章 市場障礙

第30章 附錄

第31章 調查手法

第32章 諮詢服務

第33章 免責聲明

第34章 關於DelveInsight

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0186

DelveInsight's ‘Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027.

Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm

The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe, and Japan.

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Prevalent cases, Sub-type specific prevalent cases and Gender-specific prevalent cases) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the total prevalent population of Pulmonary Arterial Hypertension (PAH) was found to be 70,557 in the year 2016.

Pulmonary Arterial Hypertension Drug Chapters

This segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the companies are developing therapeutic molecules based on Gene Therapy and Endothelin receptor antagonists which are contributing towards the market size of IPF. Detailed chapter for upcoming therapies like Aurora-GT (United Therapeutics Corporation), Macitentan (Actelion Pharmaceuticals) and Ralinepag (Arena Pharmaceuticals) have been covered in the report.

Pulmonary Arterial Hypertension Market Outlook

The Pulmonary Arterial Hypertension market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Pulmonary Arterial Hypertension in 7MM was found to be USD 4360.2 million in 2016.

Pulmonary Arterial Hypertension Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pulmonary Arterial Hypertension Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Pulmonary Arterial Hypertension Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Pulmonary Arterial Hypertension Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Pulmonary Arterial Hypertension market
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension market
  • To understand the future market competition in the Pulmonary Arterial Hypertension market.

Table of Contents

1. Key Insights

2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2016
  • 2.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2027

3. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Classification of Pulmonary Arterial Hypertension (PAH)
  • 3.4. Functional Classification of PAH
  • 3.5. Etiology
  • 3.6. Risk factors
  • 3.7. Pathophysiology
  • 3.8. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

5. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

  • 5.1. The United States
    • 5.1.1. Total Prevalent Patient Population of PAH in the United States
    • 5.1.2. Sub-type Specific Prevalence of PAH in the United States
    • 5.1.3. Gender specific Prevalence of PAH in the United States
  • 5.2. Germany
    • 5.2.1. Total Prevalent Patient Population of PAH in Germany
    • 5.2.2. Sub-type Specific Prevalence of PAH in Germany
    • 5.2.3. Gender specific Prevalence of PAH in Germany
  • 5.3. France
    • 5.3.1. Total Prevalent Patient Population of PAH in France
    • 5.3.2. Sub-type Specific Prevalence of PAH in France
    • 5.3.3. Gender specific Prevalence of PAH in France
  • 5.4. Italy
    • 5.4.1. Total Prevalent Patient Population of PAH in Italy
    • 5.4.2. Sub-type Specific Prevalence of PAH in Italy
    • 5.4.3. Gender specific Prevalence of PAH in Italy
  • 5.5. Spain
    • 5.5.1. Total Prevalent Patient Population of PAH in Spain
    • 5.5.2. Sub-type Specific Prevalence of PAH in Spain
    • 5.5.3. Gender specific Prevalence of PAH in Spain
  • 5.6. The United Kingdom
    • 5.6.1. Total Prevalent Patient Population of PAH in the UK
    • 5.6.2. Sub-type Specific Prevalence of PAH in the UK
    • 5.6.3. Gender specific Prevalence of PAH in the United Kingdom
  • 5.7. Japan
    • 5.7.1. Total Prevalent Patient Population of PAH in Japan
    • 5.7.2. Sub-type Specific Prevalence of PAH in Japan
    • 5.7.3. Gender specific Prevalence of PAH in Japan

6. Treatment Algorithm

  • 6.1. Current Treatment Practices
  • 6.2. Treatment Guidelines
    • 6.2.1. CHEST Guidelines [The United States]
  • 6.3. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

7. Unmet Needs

8. Marketed Drugs

  • 8.1. Approval and Market Presence

9. Marketed Drugs by Companies

  • 9.1. United Therapeutics Corporation
  • 9.2. Actelion Pharmaceuticals Ltd.
  • 9.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
  • 9.4. Bayer AG
  • 9.5. Pfizer

10. Safety and Efficacy of Marketed Drugs

11. Emerging Therapies

  • 11.1. Emerging Drugs Analysis

12. Global Market Size of Pulmonary Arterial Hypertension (PAH)

  • 12.1. Assumptions
  • 12.2. Market Outlook
  • 12.3. Market Size

13. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Total Market Size of PAH in 7MM

14. Pulmonary Arterial Hypertension (PAH): Market Outlook by Region

15. United States

  • 15.1. Market Outlook
  • 15.2. Assumptions
  • 15.3. Total Market size of PAH
  • 15.4. PAH Market Size by Therapeutic Class
  • 15.5. PAH Market Size by Therapies

16. EU5 Countries

  • 16.1. Market Outlook
  • 16.2. Assumptions
  • 16.3. Germany
    • 16.3.1. Total Market size of PAH
    • 16.3.2. PAH Market Size by Therapeutic Class
    • 16.3.3. PAH Market Size by Therapies
  • 16.4. France
    • 16.4.1. Total Market size of PAH
    • 16.4.2. PAH Market Size by Therapeutic Class
    • 16.4.3. PAH Market Size by Therapies
  • 16.5. Italy
    • 16.5.1. Total Market size of PAH
    • 16.5.2. PAH Market Size by Therapeutic Class
    • 16.5.3. PAH Market Size by Therapies
  • 16.6. Spain
    • 16.6.1. Total Market size of PAH
    • 16.6.2. PAH Market Size by Therapeutic Class
    • 16.6.3. PAH Market Size by Therapies
  • 16.7. United Kingdom
    • 16.7.1. Total Market size of PAH
    • 16.7.2. PAH Market Size by Therapeutic Class
    • 16.7.3. PAH Market Size by Therapies
  • 16.8. Japan
    • 16.8.1. Market Outlook
    • 16.8.2. Assumptions
    • 16.8.3. Total Market size of PAH
    • 16.8.4. PAH Market Size by Therapeutic Class
    • 16.8.5. PAH Market Size by Therapies

17. Rest of World (ROW)

  • 17.1. Assumptions
  • 17.2. Total Market size of PAH

18. Rest of Europe (ROE)

  • 18.1. Assumptions
  • 18.2. Total Market size of PAH

19. Market Drivers

20. Market Barriers

21. Appendix

  • 21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

  • Table 1: Total Prevalent Patient Population of PAH in 7MM (2016-2027)
  • Table 2: Total Prevalent Population of PAH in the United States (2016-2027)
  • Table 3: Sub-type Specific Prevalence of PAH in the United States (2016-2027)
  • Table 4: Gender specific Prevalence of PAH in the United States (2016-2027)
  • Table 5: Total Prevalent Population of PAH in Germany (2016-2027)
  • Table 6: Sub-type Specific Prevalence of PAH in Germany (2016-2027)
  • Table 7: Gender specific Prevalence of PAH in Germany (2016-2027)
  • Table 8: Total Prevalent Population of PAH in France (2016-2027)
  • Table 9: Sub-type Specific Prevalence of PAH in France (2016-2027)
  • Table 10: Gender specific Prevalence of PAH in France (2016-2027)
  • Table 11: Total Prevalent Population of PAH in Italy (2016-2027)
  • Table 12: Sub-type Specific Prevalence of PAH in Italy (2016-2027)
  • Table 13: Gender specific Prevalence of PAH in Italy (2016-2027)
  • Table 14: Total Prevalent Population of PAH in Spain (2016-2027)
  • Table 15: Sub-type Specific Prevalence of PAH in Spain (2016-2027)
  • Table 16: Gender specific Prevalence of PAH in Spain (2016-2027)
  • Table 17: Total Prevalent Population of PAH in the UK (2016-2027)
  • Table 18: Sub-type Specific Prevalence of PAH in the UK (2016-2027)
  • Table 19: Gender specific Prevalence of PAH in the UK (2016-2027)
  • Table 20: Total Prevalent Population of PAH in Japan (2016-2027)
  • Table 21: Sub-type Specific Prevalence of PAH in Japan (2016-2027)
  • Table 22: Gender specific Prevalence of PAH in Japan (2016-2027)
  • Table 23: Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence
  • Table 24: Marketed Drugs developed by United Therapeutics Corporation
  • Table 25: Marketed Drugs developed by Actelion Pharmaceuticals Ltd.
  • Table 26: Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences Inc.
  • Table 27: Marketed Drugs developed by Bayer (AG)
  • Table 28: Marketed Drugs developed by Pfizer
  • Table 29: Safety and Efficacy of Marketed Drugs
  • Table 30: Global Market Size of PAH in USD Million (2016-2027)
  • Table 31: Global Market Size of Pulmonary Arterial Hypertension (PAH) in USD Million (2015-2025)
  • Table 32: 7 Major Market Size of PAH in USD Million (2016-2027)
  • Table 33: The US Market size of PAH in USD Million (2016-2027)
  • Table 34: The U.S. Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Table 35: The US market size of PAH by Therapies in USD Million (2016-2027)
  • Table 36: Germany Market size of PAH in USD Million (2016-2027)
  • Table 37: Germany Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Table 38: Germany market size of PAH by Therapies in USD Million (2016-2027)
  • Table 39: France Market size of PAH in USD Million (2016-2027)
  • Table 40: France Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Table 41: France market size of PAH by Therapies in USD Million (2016-2027)
  • Table 42: Italy Market size of PAH in USD Million (2016-2027)
  • Table 43: Italy Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Table 44: Italy market size of PAH by Therapies in USD Million (2016-2027)
  • Table 45: Spain Market size of PAH in USD Million (2016-2027)
  • Table 46: Spain Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Table 47: Spain market size of PAH by Therapies in USD Million (2016-2027)
  • Table 48: The UK Market size of PAH in USD Million (2016-2027)
  • Table 49: The UK Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Table 50: The UK market size of PAH by Therapies in USD Million (2016-2027)
  • Table 51: Japan Market size of PAH in USD Million (2016-2027)
  • Table 52: Japan Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Table 53: Japan market size of PAH by Therapies in USD Million (2016-2027)
  • Table 54: Rest of the World (RoW) Market size of PAH in USD Million (2016-2027)
  • Table 55: Rest of Europe (RoE), Market size of PAH in USD Million (2016-2027)

List of Figures

  • Figure 1: Classification of Pulmonary Arterial Hypertension (PAH)
  • Figure 2: Functional Classification of PAH
  • Figure 3: Risk Factors of Pulmonary Arterial Hypertension
  • Figure 4: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
  • Figure 5: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
  • Figure 6: Total Prevalent Patient Population of PAH in 7MM (2016-2027)
  • Figure 7: Prevalence of PAH in the United States (2016-2027)
  • Figure 8: Sub-type Specific Prevalence of PAH in the United States (2016-2027)
  • Figure 9: Gender specific Prevalence of PAH in the United States (2016-2027)
  • Figure 10: Total Prevalent Population of PAH in Germany (2016-2027)
  • Figure 11: Sub-type Specific Prevalence of PAH in Germany (2016-2027)
  • Figure 12: Gender specific Prevalence of PAH in Germany (2016-2027)
  • Figure 13: Total Prevalent Population of PAH in France (2016-2027)
  • Figure 14: Sub-type Specific Prevalence of PAH in France (2016-2027)
  • Figure 15: Gender specific Prevalence of PAH in France (2016-2027)
  • Figure 16: Total Prevalent Population of PAH in Italy (2016-2027)
  • Figure 17: Sub-type Specific Prevalence of PAH in Italy (2016-2027)
  • Figure 18: Gender specific Prevalence of PAH in Italy (2016-2027)
  • Figure 19: Total Prevalent Population of PAH in Spain (2016-2027)
  • Figure 20: Sub-type Specific Prevalence of PAH in Spain (2016-2027)
  • Figure 21: Gender specific Prevalence of PAH in Spain (2016-2027)
  • Figure 22: Total Prevalent Population of PAH in the UK (2016-2027)
  • Figure 23: Sub-type Specific Prevalence of PAH in the UK (2016-2027)
  • Figure 24: Gender specific Prevalence of PAH in the United Kingdom (2016-2027)
  • Figure 25: Total Prevalent Population of PAH in Japan (2016-2027)
  • Figure 26: Sub-type Specific Prevalence of PAH in Japan (2016-2027)
  • Figure 27: Gender specific Prevalence of PAH in Japan (2016-2027)
  • Figure 28: Treatment Options for Pulmonary Arterial Hypertension (PAH)
  • Figure 29: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)
  • Figure 30: Global Market Size of PAH USD Million (2016-2027)
  • Figure 31: Global Market Size of Pulmonary Arterial Hypertension (PAH) in USD Million (2015-2025)
  • Figure 32: 7 Major Market Size of PAH in USD Million (2016-2027)
  • Figure 33: Market Size of PAH in the United States, USD Millions (2016-2027)
  • Figure 34: The U.S. Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Figure 35: The U.S. market size of PAH by therapies in USD Million (2016-2027)
  • Figure 36: Market Size of PAH in Germany, USD Millions (2016-2027)
  • Figure 37: Germany Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Figure 38: Germany market size of PAH by therapies in USD Million (2016-2027)
  • Figure 39: Market Size of PAH in France, USD Millions (2016-2027)
  • Figure 40: France Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Figure 41: France market size of PAH by therapies in USD Million (2016-2027)
  • Figure 42: Market Size of PAH in Italy, USD Millions (2016-2027)
  • Figure 43: Italy Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Figure 44: Italy market size of PAH by therapies in USD Million (2016-2027)
  • Figure 45: Market Size of PAH in Spain, USD Millions (2016-2027)
  • Figure 46: Spain Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Figure 47: Spain market size of PAH by therapies in USD Million (2016-2027)
  • Figure 48: Market Size of PAH in the UK, USD Millions (2016-2027)
  • Figure 49: The UK Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Figure 50: The UK market size of PAH by therapies in USD Million (2016-2027)
  • Figure 51: Market Size of PAH in Japan, USD Millions (2016-2027)
  • Figure 52: Japan Market size of PAH by Therapeutic Class in USD Million (2016-2027)
  • Figure 53: Japan market size of PAH by therapies in USD Million (2016-2027)
  • Figure 54: Market Size of PAH in Rest of the World (RoW), USD Millions (2016-2027)
  • Figure 55: Market Size of PAH in Rest of Europe (RoE), USD Millions (2016-2027)
Back to Top